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Background: Disparities in the use of invasive coronary artery revascularisation procedures to manage acute
myocardial infarction (AMI) have been found in several developed economies. Factors such as socio-economic
status, income and funding source may influence the use of invasive procedures and have also been associated
with ongoing care. The objectives of this study were to determine whether outcomes for patients at one and
five years after AMI treated with first-ever percutaneous coronary intervention (PCI) were the same for public and
privately funded patients.
Methods: Retrospective, population-based cohort study using linked data to identify 30-day survivors of AMI
treated with PCI in the index admission between 1995 and 2008 in Western Australian hospitals. The main outcome
measures were admission for another PCI, re-AMI, and all-cause and cardiac mortality at one and five years.
Results: At one year, private patients were at greater adjusted risk for another PCI (HR 1.62 [1.36 – 1.94]; p < 0.001)
than public patients, and more likely to have an additional revascularisation procedure from 90 days to 5 years (HR
1.33 [1.11 – 1.58]; p < 0.001). They were at less risk for all-cause death within five years (HR 0.69 [0.62–0.91]; p = 0.01)
with a trend to reduced risk for cardiac death and re-AMI.
Conclusions: Treatment as a private patient for AMI with first PCI is associated with an increased likelihood of
additional coronary revascularisation procedure within 12 months and to five years, and a reduced risk for all-cause
mortality to 5 years. While additional procedures were not associated with poorer outcomes, there was no clear
relationship between better outcomes and additional procedures. Other lifestyle and health care factors may
contribute to the significant reduction in all-cause mortality and the trends to reduced hazard for AMI and cardiac
death among private patients.
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Studies from several developed countries, including
those with universal health care systems, report access
to cardiac services for the management of acute myocardial
infarction (AMI) may be influenced by factors other than
clinical need. Socio-economic status [1], income [2,3] and
funding source [4-6] have been found to be associated
with disparities in the use of invasive procedures such as
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and with mortality. Similar factors have been shown
to influence care after AMI, both in use of preventive
medications [7-9] and further revascularisation procedures
[9-11], while under-insurance has been linked to long-term
survival after AMI [12].
This population-based study aims to determine whether
funding source is associated with patient outcomes after a
first-ever PCI for AMI. We used data linkage to compare
repeat revascularisation, re-AMI, and all-cause and
cardiac mortality at one and five years for public and
privately-funded patients admitted from 1995 to 2008.ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Data source
This study uses linked data extracted from the Western
Australia (WA) Data Linkage System by the Data
Linkage Branch of the Health Department of Western
Australia. Briefly, the Data Linkage System systematically
links available administrative health data (including hospital
admissions and discharges and deaths) for the state. Re-
cords are collated under individual unique identifiers.
Computerised probabilistic matching of patient names
and other identifiers is used, with poorly-matched or un-
matched records reviewed by a Linkage Officer. Validation
of the matching for the hospital morbidity data estimated
invalid links (false positives) and missed links (false
negatives) at 0.11% each [13]. Hospitalisation data were
available from 1985, providing 10 years of look-back.
Case ascertainment
Patient selection, the identification of comorbidities,
cardiac-related diagnoses, procedures and cause of death
were based on the World Health Organization (WHO)
International Classification of Disease (ICD) versions 9,
9-CM (Clinically Modified) and 10-AM (Australian
Modification).
The study cohort included all individuals aged 35 years
and over who were admitted to WA hospitals between
1 January 1995 and 31 December 2008 for an AMI
(ICD-9, -9-CM ‘410.’, ICD-10 ‘I21’) as a principal
diagnosis, were treated during admission with a first-ever
PCI, and who had not undergone any type of revasculari-
sation procedure in the previous 10 years. Revascularisa-
tion procedures were identified by codes for PCI (ICD–9
'5-363'; -9CM '36.01, 36.02, 36.05-36.07; ICD-10 blocks
670, 671) and CABG (ICD-9 '5-361', ICD-9-CM '36.10-
36.19', ICD-10 blocks '672-679') (ICD–9 '5-361-5.362', -9CM
'36.01-36.09, 36.10-36.2', ICD-10 blocks '670 to 679'). Those
admitted as an emergency (i.e. not an elective admission)
were selected, and only those who survived 30 days from
admission were included in the survival analyses. This
was done to reduce the possibility of case selection bias as
most cases, public and private, are initially admitted to an
emergency department in a tertiary hospital. Selection
of funding status usually occurs after the initial critical care
period so early in-hospital deaths would be disproportion-
ately classified as 'publicly-funded'.
Outcomes measures and study variables
Outcomes were events within one year (cases to end
2007, n = 5451) and cumulative events of first additional
PCI after the index procedure, first readmission for AMI,
and all-cause and cardiac death to five years. One year
outcomes were measured from 30-days, and five-year
outcomes were measured from 90 days post-index
admission to minimise counting re- admissions andprocedures related to care for the acute episode. Coronary
artery bypass grafting (CABG) was included in the
additional revascularisation procedure to five years.
Re-admissions could be either emergency (unplanned)
or booked (planned) admissions.
Patients were grouped by decades of age (<50 years,
50-59, 60-69, 70-79 and 80 years and over).
The index admission funding source was used to
categorise patients as public or private. Public patients were
all those who elected treatment under the Australian Health
Care Agreements and Reciprocal Health Care Agreements.
Private patients included those funded through private
health insurance or self-funded (regardless of whether
treated in a public or private hospital). As Australians can
move freely in and out of private insurance, with multiple
changes in status possible before and after the index
admission, funding source was not used as a time-dependent
covariate.
The linked data included socio-economic and geo-
graphical data in the form of the Index of Relative
Socio-Economic Disadvantage (IRSD) for the area in
which the patient resides, and the Accessibility/Remoteness
Index of Australia (ARIA+), which indicates the road
distance from and access to major services. These
data were collected in census years 1996, 2001 and
2006 [14-16]. The scores used were those released
nearest (before or after) the date of the index admission.
Percentiles of the IRSD were used to categorise the
area of residence into quartiles of relative socio-economic
disadvantage, with Q1 (highest scores) being most
disadvantaged. ARIA + values of 1 or 2 (i.e. major city and
inner regional) were categorised as ‘urban/regional’ and
values of 3, 4 or 5 (i.e. outer regional, remote and very
remote) as ‘rural/remote’ [17]. These data were not
available for 11% of patients.
A history of prior AMI, heart failure (HF) (ICD-9/9-CM
'428.' and ICD-10 'I50.') and the number of admission for
ischemic heart disease (IHD) (ICD-9/9-CM '410.'-'414.'
and ICD-10 'I20.'-'I25.') in the previous decade were
identified from hospital morbidity data. IHD admissions
were categorised as ‘none’ or ‘1 or more’. Re-AMI
(non-fatal new AMI) was defined as re-admission
with a principal diagnosis of AMI. Other comorbid
conditions were identified and weighted to obtain a
Charlson Comorbidity Index score for each patient, using
methods developed for ICD-9 and ICD-10 [18,19], exclud-
ing the condition responsible for hospital admission (AMI)
and existing HF. The comorbidity scores were categorised
as ‘0’, ‘1-2’, ‘3-5’ and ‘≥6’.
Statistics
Descriptive statistics were used to examine the demographic
and clinical characteristics of the cohort, with the χ2
tests of independence used to compare categorical variables
Table 1 Demographic and clinical characteristics of 6, 176
public and private patients who survived 30 days from






n (%) n (%) p value
Mean age (SD) years 61.3 (12.6) 61.2 (10.8) 0.75
Female 1125 (25.3) 358 (20.7) <0.001
Indigenous 171 (3.8) 4 (0.2) -
Quartile of IRSD*
Q1 1487 (33) 264 (15)
Q2 1051 (24) 299 (17)
Q3 1222 (28) 553 (32)
Q4 690 (15) 610 (35) <0.001
Rural or remote residence 414 (9.3) 126 (7.3) 0.01
Previous IHD admission 367 (8.2) 123 (7.1) 0.16
History of AMI 329 (7.4) 118 (6.8) 0.48
History of heart failure 86 (1.9) 24 (1.4) 0.16
Heart failure (index
admission)
390 (8.8) 114 (6.6) 0.005
Single-vessel PCI 3948 (89) 1469 (85) <0.001
Charlson Comorbidity
'Score'
0 2038 (45.8) 914 (52.9)
1-2 1366 (30.7) 521 (30.2)
3-5 670 (15.1) 200 (11.6)
≥6 376 (8.4) 91 (5.3) <0.001
*Index of Relative Socio-economic Disadvantage - Q1 = greatest disadvantage.
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of mean age.
Kaplan-Meier (K-M) techniques were used to construct
survival curves, with the log-rank test used to test differ-
ences in survival for each factor. Predictor variables signifi-
cantly associated with the outcomes (all-cause and cardiac
mortality, re-AMI, and readmission with an additional PCI
to 1 year, and any additional revascularisation procedure to
5-years) were entered into the final multivariate models.
After ensuring the assumptions of proportionality were met,
Cox regression models (backwards selection) were used to
identify the predictor variables associated with all-cause and
cardiac mortality, re-AMI, and readmission with a PCI to
1 year and any revascularisation procedure to 5-years. Cases
were censored at 31st December 2008. A two-sided ‘p’ value
of 0.05 or less was considered statistically significant.
The data were analysed using SAS version 9.2 (SAS
Institute Inc., Cary NC, USA) and IBM SPSS Statistics
for Windows, Version 21.0. Armonk, NY: IBM Corp.
statistical software.
Ethics
The study uses de-identified linked administrative data for
which we have received a waiver of informed consent under
the provisions of section 2.3.6 of the Australian National
Statement on Ethical Conduct in Human Research 2007.
The study was approved by the Human Research Ethics
Committees at the University of Western Australia and
Health Department of Western Australia.
Results
During 1995-2008, 6,941 patients with AMI treated with an
emergency (non-elective) first-ever PCI, and who survived
for 30 days after admission to hospital, were identified. Of
these, the 6,176 patients (89%) with complete data for all
variables formed the study cohort; 4,450 (72%) being public
patients. The demographic and clinical characteristics
of the patients are shown in Table 1. It was the first
cardiac admission within 10 years for 92% of cases.
Of the publicly-funded patients 97% underwent their first
PCI in a public hospital, while 66% of private patients
were also treated initially in a public hospital. Of all PCIs
performed, over 90% included stent insertion for both
public and private patients. A greater proportion of private
patients underwent another revascularisation procedure
within 90 days (Table 2).
Patients in the ‘most disadvantaged’ quartile had higher
comorbidity, with a significant trend for the association
between increasing disadvantage and increasing comorbidity
(χ2 trend 66.4, p < 0.001).
Study cohort
Compared to public patients a greater proportion of
private patients were men, in quartile four of IRSD(least disadvantaged), and were in the lower categories
of comorbidity. During the index admission a smaller
proportion of private patients had a HF diagnosis recorded
(indicating either a complication or a history of HF) while
multi-vessel PCI was more frequent.
The 763 (11%) patients excluded for missing data did
not differ in age, sex, proportion of private patients, or
comorbidity. They were more likely to have had a previous
admission for IHD (14% vs 8%, p < 0.001) and a history of
AMI (14% vs 7% p < 0.001), but not HF. The KM survival
estimates for both those with and without missing
data were 0.98 (SE = 0.002, 0.004) at 12 months and
0.91 (SE = 0.006, 0.013) at 5 years.
One year outcomes
There were 91 deaths within 12 months, of which half
(46) were cardiac deaths. The outcomes at one year for
publicly- and privately-funded patients are shown in Table 2.
The hazard ratios (HR)s for public versus privately funded
patients were obtained after adjustment for age-group,
sex, HF, a history of AMI, prior admission for other
IHD, Charlson Comorbidity Index category, quartile
of IRSD, ARIA + (urban vs rural/remote) and single
Table 2 Events and outcomes at 90 days, and one and
five years after first PCI among 6,176 publicly- and





Within 90 days of index admission
Additional PCI in 30 days 88 (2) 50 (3) 0.01
Additional PCI or CABG in 90 days 275 (6) 190 (11) <0.001
12 months (from 30 days post
admission) n = 5451
n = 3961 n = 1490
Additional PCI 329 (8) 193 (13) <0.001
Re-AMI 158 (4) 65 (4) 0.29
Crude mortality (all-cause) 78 (2) 13 (1) 0.01
Cardiac death (% of all deaths) 42 (54) 4 (31) -
5 years (from 90 days post admission)
n = 6148
n = 4427 n = 1721
Survival to additional revascularisation 0.91 0.90 0.004
Survival to re-AMI 0.94 0.96 0.003
Survival (all-cause death) 0.90 0.95 <0.001
Survival (cardiac deaths) 0.96 0.98 <0.01
Table 3 Association of funding source with outcomes
(adjusted hazard ratio) at one and five years after AMI
with first-ever PCI
Outcomes Hazard ratio (95% CI) p
Private vs public
funding
12 months (from 30 days
post admission)
Additional PCI 1.62 (1.36-1.94) <0.001
Re-AMI 1.37 (1.01-1.86) 0.04
All-cause mortality 0.61 (0.34-1.11) NS
Cardiac death 0.42 (0.18-0.99) 0.05
5 years (from 90 days post
admission)
Additional PCI or CABG 1.33 (1.11-1.58) 0.002
Re-AMI 0.77 (0.59-1.01) 0.06
All-cause mortality 0.69 (0.52-0.91) 0.01
Cardiac death 0.63 (0.41-0.98) 0.04
Models adjusted for decade of age, sex, histories of AMI and HF, number of
IHD admissions, HF in the index admission, Charlson Comorbidity Index score,
single- or multi-vessel index PCI, Index of Relative Socio-economic Disadvantage
(IRSD), ARIA + category and an additional revascularisation procedure or re-AMI in
90 days for 5-year outcomes.
PCI = percutaneous coronary intervention, AMI = acute myocardial infarction,
CABG = coronary artery bypass graft.
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30 days was also included in the models for re-AMI
and survival to 1 year (Table 3).Additional PCI
There were 164 additional PCI within 30-days of the index
procedure among 30-day survivors of AMI (either during
the index admission, which could include inter-hospital
transfer, or in a re-admission) and 465 additional revascu-
larisation procedures within 90 days. An additional PCI
after 30 days and within one year was more frequent
among privately-funded patients (Table 2). After adjust-
ment for all clinical and demographic variables private
patients were at an increased ‘hazard’ for an additional PCI
within 12 months of the index AMI (Table 3), as were those
with greater comorbidity.Re-AMI
There were 223 patients re-admitted for AMI within
the first year (Table 2). The association with funding
source reached statistical significance, but with a
broad confidence interval with the trend favouring
privately-funded patients. There a significant interaction
between funding source and IRSD (socioeconomic
indicator). Being among the ‘least disadvantaged’ patients
was associated with lower risk for re-AMI compared
to the most disadvantaged. Greater comorbidity was
associated with increased risk for re-AMI, as was HF
recorded in the index admission.Mortality
All-cause and cardiac deaths are shown in Table 2.
Funding source was not associated with all-cause
mortality to one year, but with a trend to a reduced
hazard for cardiac death for privately-funded patients
on low numbers (Table 3). Risk increased with older
age, a history of HF, and increasing comorbidity.
Five year outcomes
There were 29 deaths between 30 and 90 days of admission,
leaving 6, 147 patients for follow-up to five years. Only11
re-AMIs were recorded between 30-90 days. Cumulative
survival to each outcome to five years favoured privately-
funded patients (Table 2).
Additional revascularisation procedure
Privately-funded patients were more likely to have a
readmission with a revascularisation procedure within
5 years (Table 3). The ‘hazard’ for undergoing an additional
revascularisation procedure decreased with increasing age
while those with greater comorbidity were more likely to
have an additional procedure as were those who underwent
a multi-vessel PCI in the index admission.
Re-AMI
There was a trend to reduced risk for re-admission
for AMI after 90 days among privately-funded patients
although the confidence interval crossed unity (Table 3).
Patients with HF in the index admission, those with
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multi-vessel index PCI were at increased risk for re-AMI,
while patients aged between 50-80 years were at less
risk for re-AMI than those aged <50 years; risk was
non-significantly higher for those aged 80 years or more.
Survival
Survival to all-cause death and cardiac death at 5 years
was poorer for publicly-funded patients (Table 2). The
hazard for all-cause death at five years was reduced for
those treated as private patients in the index admission
(Table 3), with the effect of funding source seen across
all age groups. Risk factors associated with an increased
risk for death were age over 70 years, a history of heart
failure and increasing comorbidity. Neither re-AMI nor
an additional PCI in the 90 days after admission were
associated with 5-year survival.
The reduction in hazard for a cardiac death for
privately-funded patients was of statistical significance but
the confidence interval was broad (Table 3). Older age and
greater comorbidity were predictors for a cardiac death,
and a history of HF more than quadrupled the hazard.
Discussion
As expected, the factors most frequently associated with
an increased risk for re-admission or death, older age,
greater burden of comorbidity, HF and a history of IHD
[20-22], were significant predictors of outcomes in this
study. In addition, the source of patient funding in the
index admission was associated with the likelihood of
having an additional revascularisation procedure, and of
reduced hazard of death to five years.
Those electing treatment as private patients, whether
in a public or private hospital, were significantly more
likely than public patients to undergo an additional
procedure within 90 days and 12 months.
Explanations for the increased rates of additional
procedures among private patients include a greater need
for a repeat procedure to manage complications such as
in-stent thrombosis, and more severe CAD. As cardiac
deaths and readmissions for AMI were similarly low in
the first year for both groups, and long-term survival was
better for private patients, this explanation is unlikely.
As well as an additional PCI within the first three
months after the index AMI, private patients were more
also likely to have multi-vessel PCI during the index
admission. While around 50% of ST-elevation AMI
(STEMI) patients suffer multi-vessel disease, not all
patients will undergo multi-vessel revascularisation, either
at the index PCI or as a staged procedure [23]. While a
staged strategy (treating non-culprit lesions in a planned
intervention of additional PCI) is associated with lower
risk for mortality than multi-vessel PCI during the acute
management of AMI [23,24] private patients appearto be in receipt of greater rates of both. Although
these administrative data are insufficient to identify
the number of diseased vessels at presentation, or the
revascularisation strategy, the greater use of multi-vessel
PCI during the index admission, and of additional PCI after
discharge, suggests a greater focus on achieving complete
revascularisation among privately-funded patients.
Less aggressive revascularisation among public patients
may be to their disadvantage, as evidence from clinical
trials and registries for patients with acute coronary
syndromes or stable coronary disease treated with
PCI suggests that incomplete revascularisation of
multi-vessel disease is associated with a greater risk for
major adverse coronary and cerebrovascular events and
deaths in the longer term [24-26]. However, in our
modelling, an additional revascularisation procedure
within the first 30 to 90 days was not independently
predictive of a re-AMI, or survival at 1 or 5 years;
thus more aggressive interventional treatment did not
explain the differences in long-term survival between
private and public patients.
The greater use of additional procedures among
private patients may also be related to the different
level of access to PCI in the public and the private
sectors. Patients treated for AMI in private hospitals
in the Australian state of Victoria were found to be
2-3 times more likely to undergo angiography and
PCI than public patients in public hospitals [6]. The
authors concluded that fee-for-service payments might
generate a financial incentive in the private system
not present in the public system. This incentive could
contribute to a tendency to re-admit private patients
for an additional PCI, as seen in our study.
In a study of socio-economic inequalities and the use
of coronary angiography and revascularisation proce-
dures in Western Australia the 'more advantaged' patients
admitted with angina, but not those with AMI, had higher
rates of coronary procedures [27]. Similarly, in our cohort
of patients with AMI, funding source, but not the Index
of Relative Socio-economic Disadvantage, was associ-
ated with the use of procedures. The IRSD was inde-
pendently associated only with risk for re-AMI within
12 months, with the ‘least disadvantaged’ only half as
likely to suffer a re-AMI as those’ most disadvantaged’.
This may reflect the overall poorer health status associated
with socio-economic disadvantage, including greater
comorbidity and a greater prevalence of risk factors [28,29],
or poorer access to, or uptake of, secondary prevention and
cardiac rehabilitation after discharge [7,30].
There was a reduced hazard for all-cause and cardiac
death to 5 years among private patients, with a trend
towards a reduced risk for re-AMI (although the p-value
failed to reach statistical significance). While PCI has been
associated with reductions of mortality and non-fatal AMI
Bradshaw et al. BMC Health Services Research 2014, 14:405 Page 6 of 7
http://www.biomedcentral.com/1472-6963/14/405compared to optimal medical therapy in high-risk patients
with non-STEMI and unstable angina to five years [31],
this was not the case for stable angina [32] suggesting that
an additional PCI, per se, is unlikely to improve survival. If
the additional procedures among private patients in this
study were in response to worsening coronary artery
disease, we were unable to convincingly demonstrate
a benefit of this strategy in reducing re-AMI, perhaps
due to lack of power, as event numbers were low.
The reduced all-cause mortality at five years among
those treated as private patients could not be attributed
with certainty to a reduction in re-AMI or cardiac
deaths, although there were trends to reduced hazards for
cardiac death at one and five years and, less convincingly,
re-AMI. Alternative explanations for the better overall
survival among private patients include the overall better
health of patients who can afford private care. The
probability that public patients have poorer health is
indicated by the greater proportion of public patients
suffering HF and other comorbidities, but information
on the severity of coronary disease and other risks is
not available from the data. Greater clinical detail
would help determine whether differences in the
management of private and public patients are patient-
related or practice-related.
Overall, greater use of an additional revascularisation
procedure among the generally healthier private patients
was to their apparent benefit, but the reductions in the
long-term hazard for a re-AMI or cardiac death were of
borderline statistical significance. Patients who choose
(and can afford) private funding may also benefit from
better care after discharge, leading to a reduction in
risk for re-AMI in the longer term and to better survival,
regardless of interventional management.Strengths
The strength of this study is the availability of 22 years
of well-validated [33], routinely-collected and audited data
for all inpatient episodes in all WA public and private
hospitals.
Although 11% of the population cohort had missing
socioeconomic status or residential locality data, there
was no difference in survival for those excluded; the
findings are therefore representative of outcomes for
the WA population.Limitations
We lacked clinical detail on the severity of coronary
artery disease and on the type of PCI (primary, rescue,
facilitated or in response to angiography findings). In
addition, ST-segment elevation AMI (STEMI) and
non-STEMI are not consistently identified in ICD coding.
There is no information on other risk factors, such assmoking behaviour, or on medications. All of these factors
may influence outcomes.Conclusions
Admission as a private patient for an AMI treated with a
first-ever PCI is associated with a greater likelihood of
having an additional revascularisation procedure early or
late after admission, and reduced risk for all-cause
mortality to five years compared to public patients.
There was no apparent risk for worse outcomes associated
with the more aggressive interventional management
among private patients, although additional procedures
within 90 days of the index PCI did not predict reduced
risk for all-cause or cardiac death, or re-AMI. The benefits
among those who can afford private health care may be
associated with more aggressive treatment, or with
other factors related to their generally higher socio-
economic status. It remains uncertain as to whether
public patients, who have a greater burden of comor-
bidity and likely poorer overall health status, would
benefit from more aggressive management of their
coronary artery disease.
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